newsfilter
← Earnings
Earnings Releases·

Viking Therapeutics — Third Quarter 2026 Earnings Summary

Viking Therapeutics reported a net loss of $183.2 million for the third quarter of 2026, driven by increased research and development expenses related to its obesity franchise. The company advanced its clinical pipeline by initiating the SUNRISE Phase 3 trials for its oral VK2735 formulation and announced positive top-line results from the maintenance dosing study for the subcutaneous version. Additionally, the Phase 1 single ascending dose study for the amylin agonist VK3019 is nearing completion, with a multiple ascending dose study expected to begin in the first quarter of 2027. Viking ended the quarter with a cash position of $960 million following the closure of concurrent public offerings of common stock and convertible senior notes.

Company
VIKING THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology